The nuclear medicine group of Siemens Medical Systems has startedbuilding the first gamma camera detectors using sodium iodidecrystals grown at a new facility the vendor has built at its HoffmanEstates, IL, headquarters. The new crystal-growing factory
The nuclear medicine group of Siemens Medical Systems has startedbuilding the first gamma camera detectors using sodium iodidecrystals grown at a new facility the vendor has built at its HoffmanEstates, IL, headquarters. The new crystal-growing factory isexpected to improve Siemens' nuclear medicine R&D effort andwill reduce the company's dependence on French chemical consortiumSaint-Gobain, which was the only manufacturer of the crystalsin the world until the Siemens program came online, accordingto Paul Kasulis, director of new business units.
Siemens announced at last year's Society of Nuclear Medicinemeeting that it had acquired crystal-growing technology from theUkrainian Institute for Single Crystals in Kharkov and was transferringUkrainian engineers to the U.S. to create its own supply. At thisyear's SNM conference, Siemens said it had built the first detectorsusing the crystals and would begin life-cycle testing of the devices.The company expects to begin production shipments of cameras withthe home-grown crystals in the fall, Kasulis said.
Using crystals of its own manufacture confers a number of advantagesbeyond just self-sufficiency, according to Kasulis. Siemens willnow be able to design crystals to its own specifications for specializeduses such as high-energy imaging or organ-specific applications.
"They will be used commercially, but the windfall is toget crystals pre-commercial -- in other words, to get crystalsto do whatever you want on a research basis," Kasulis said.
Siemens will also supply its crystals to nuclear medicine researchers,as well as other gamma camera vendors. The company has receivedgood manufacturing practices (GMP) approval for the crystal-growingplant and the nuclear medicine group has ISO 9000 certification.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.